Phaseline

Companies › Merck KGaA

Merck KGaA: clinical trials, targets and expected readouts

18 active drug programs in 73 registered trials: 35 Phase 2, 26 Phase 1, 11 Phase 3, 1 Phase 4; Oncology, Immunology, Other, Genitourinary; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Avelumab
Programmed cell death 1 ligand 1 other
CD274Phase 3Solid Tumors; Locally Advanced or Metastatic Urothelial Carcinoma; Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable; HNSCC …Nov 2026
Follitropin (MBJ-0011)
Follicle stimulating hormone receptor agonist
FSHRPhase 3InfertilitySep 2027
Enpatoran
Toll-like receptor 8 antagonist; Toll-like receptor 7 antagonist
TLR8, TLR7Phase 3Systemic Lupus Erythematosus (SLE); Systematic Lupus ErythematosusMay 2029
Precemtabart tocentecan
Topoisomerase I inhibitor
–Phase 3Metastatic Colorectal CancerOct 2029
M6223–Phase 2Locally Advanced or Metastatic Urothelial CarcinomaJan 2027
NKTR-255–Phase 2Locally Advanced or Metastatic Urothelial Carcinoma; B Acute Lymphoblastic LeukemiaJan 2027
Enpatoran (M5049)
Toll-like receptor 8 antagonist; Toll-like receptor 7 antagonist
TLR8, TLR7Phase 2Systemic Lupus ErythematosusAug 2028
Pimicotinib
CSF1R tyrosine kinase inhibitor
CSF1RPhase 2Tenosynovial Giant Cell TumorAug 2028
Tepotinib
Hepatocyte growth factor receptor inhibitor
METPhase 2Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification; Advanced Non Small Cell Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma; Non-Small Cell Lung Cancer Metastatic …–
Mirdametinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 1HealthyNov 2026
Tuvusertib (M1774)–Phase 1Metastatic or Locally Advanced Unresectable Solid Tumors; Advanced Solid Tumor; Endometrial CancerNov 2026
M9466–Phase 1Advanced Solid TumorFeb 2027
M3554
anti-GD2 antibody-drug conjugate
GD2Phase 1Advanced Solid TumorApr 2027
M5542–Phase 1HealthyDec 2027
M9140
anti-CEACAM5 antibody-drug conjugate
CEACAM5Phase 1Colorectal Cancer; Solid TumorsDec 2027
M7437
anti-Ly6E antibody-drug conjugate with exatecan payload
LY6EPhase 1Advanced Solid TumorsSep 2028
M0324–Phase 1Advanced Solid TumorFeb 2029
M9140
anti-CEACAM5 antibody-drug conjugate
CEACAM5Phase 1Solid Tumors–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03498378AvelumabPhase 1Head and Neck Squamous Cell CarcinomaOncologyFeb 2020
NCT04004442AvelumabPhase 1Urothelial CarcinomaOncologyApr 2022
NCT02864992TepotinibPhase 2Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET AmplificationOncologyMay 2022
NCT03979131AvelumabPhase 2Gastroesophageal Junction AdenocarcinomaOncologyMar 2023
NCT04678362AvelumabPhase 2Urothelial CarcinomaOncologyJul 2023
NCT06806046M9140Phase 1Solid TumorsOncologySep 2026
NCT05464030M9140Phase 1Colorectal CancerOncologyOct 2026
NCT04291885AvelumabPhase 2Merkel Cell CarcinomaOncologyNov 2026
NCT02912572AvelumabPhase 2Metastatic Endometrial CancerOncologyNov 2026
NCT07840612MirdametinibPhase 1HealthyOtherNov 2026
NCT03815643AvelumabPhase 3Solid TumorsOncologyNov 2026
NCT04170153Tuvusertib (M1774)Phase 1Metastatic or Locally Advanced Unresectable Solid TumorsOncologyNov 2026
NCT04848519AvelumabPhase 2Locally Advanced Bladder Urothelial CarcinomaOncologyDec 2026
NCT05600127AvelumabPhase 2Urothelial CarcinomaOncologyDec 2026
NCT04261855AvelumabPhase 1Metastatic Merkel Cell CarcinomaOncologyDec 2026
NCT03573648AvelumabPhase 2Breast CancerOncologyDec 2026
NCT03147287AvelumabPhase 2Metastatic Breast CancerOncologyDec 2026
NCT03391479AvelumabPhase 2Penile CancerOncologyDec 2026
NCT06820255AvelumabPhase 4Bladder (Urothelial, Transitional Cell) Cancer Metastatic or UnresectableOncologyJan 2027
NCT05327530AvelumabPhase 2Locally Advanced or Metastatic Urothelial CarcinomaOncologyJan 2027
NCT05327530M6223Phase 2Locally Advanced or Metastatic Urothelial CarcinomaOncologyJan 2027
NCT05327530NKTR-255Phase 2Locally Advanced or Metastatic Urothelial CarcinomaOncologyJan 2027
NCT03971409AvelumabPhase 2Stage III Breast CancerOncologyJan 2027
NCT06421935M9466Phase 1Advanced Solid TumorOncologyFeb 2027
NCT06421935Tuvusertib (M1774)Phase 1Advanced Solid TumorOncologyFeb 2027
NCT04792073AvelumabPhase 2Merkel Cell CarcinomaOncologyMar 2027
NCT03076554AvelumabPhase 2ThymomaOncologyMar 2027
NCT04387084AvelumabPhase 1Advanced Malignant Skin NeoplasmOncologyMar 2027
NCT03964532AvelumabPhase 1Breast CancerOncologyApr 2027
NCT06641908M3554Phase 1Advanced Solid TumorOncologyApr 2027
NCT04071236AvelumabPhase 1Metastatic Castration-Resistant Prostate CarcinomaOncologyApr 2027
NCT03414658AvelumabPhase 2Breast CancerOncologyMay 2027
NCT06892860AvelumabPhase 2Urinary Bladder NeoplasmsOncologyJun 2027
NCT04068194AvelumabPhase 1Locally Advanced Malignant Solid NeoplasmOncologyJul 2027
NCT04841148AvelumabPhase 2Breast CancerOncologyJul 2027
NCT04360941AvelumabPhase 1Triple Negative Breast CancerOncologyJul 2027
NCT06869473AvelumabPhase 2Head and Neck Squamous Cell Carcinoma (HNSCC)OncologyAug 2027
NCT06518564AvelumabPhase 2Endometrial CancerOncologyAug 2027
NCT06518564Tuvusertib (M1774)Phase 2Endometrial CancerOncologyAug 2027
NCT06228066AvelumabPhase 2Small Cell Carcinoma of the BladderOncologySep 2027
NCT07340827Follitropin (MBJ-0011)Phase 3InfertilityGenitourinarySep 2027
NCT06640725AvelumabPhase 2Recurrent or Metastatic Squamous Cell Carcinoma of Head and NeckOncologyOct 2027
NCT02999087AvelumabPhase 3HNSCCOncologyDec 2027
NCT02767063AvelumabPhase 1Leukemia, Myeloid, Chronic-PhaseOncologyDec 2027
NCT06577337M5542Phase 1HealthyOtherDec 2027
NCT06710132M9140Phase 1Solid TumorsOncologyDec 2027
NCT06083857TepotinibPhase 1Non-small Cell Lung CancerOncologyDec 2027
NCT05947500AvelumabPhase 2Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8OncologyJan 2028
NCT05782361TepotinibPhase 1Advanced CancerOncologyMar 2028
NCT06908993TepotinibPhase 3Advanced Non Small Cell Lung CancerOncologyMar 2028
NCT06031688TepotinibPhase 2Recurrent Lung Non-Small Cell CarcinomaOncologyMay 2028
NCT05327686AvelumabPhase 2Metastatic Renal Cell CarcinomaOncologyJun 2028
NCT05540327Enpatoran (M5049)Phase 2Systemic Lupus ErythematosusImmunologyAug 2028
NCT06686381AvelumabPhase 2Muscle-invasive Bladder CancerOncologyAug 2028
NCT07499362PimicotinibPhase 2Tenosynovial Giant Cell TumorOncologyAug 2028
NCT07360314M7437Phase 1Advanced Solid TumorsOncologySep 2028
NCT04396223AvelumabPhase 1Gestational Trophoblastic Neoplasias (GTN)OncologyOct 2028
NCT03944941AvelumabPhase 2Skin Squamous Cell CarcinomaOncologyDec 2028
NCT03271372AvelumabPhase 3Stage III Merkel Cell Carcinoma AJCC v8OncologyJan 2029
NCT07166601M0324Phase 1Advanced Solid TumorOncologyFeb 2029

The 60 nearest readouts of 73 trials; the rest in the app.

Targets

TLR8 (2) TLR7 (2) CEACAM5 (2) CSF1R (1) MAP2K1 (1) MAP2K2 (1) LY6E (1) CD274 (1) GD2 (1) MET (1) FSHR (1)

Companies with the same targets

Roche Pfizer Eikon Therapeutics United Immunity Beeline Medicines HighField Biopharmaceuticals Ascendis Pharma Oncology Division Bolt Biotherapeutics Inimmune Chongqing Precision Biotech

Companies built like this

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai Henlius Biotech Sichuan Kelun-Biotech Biopharmaceutical Shenyang Sunshine Pharmaceutical Shanghai Hengrui Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.